FDA expands Glaxo-Ligand Promacta to hepatitis C patients

Tue Nov 20, 2012 2:22am IST

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008.

Credit: Reuters/Toby Melville

Related Topics

Stocks

   
Rajalakshmi (C), 28, smiles after winning the Miss Wheelchair India beauty pageant in Mumbai November 26, 2014. REUTERS/Danish Siddiqui

Miss Wheelchair India

Seven women from across India participated in the country's second wheelchair beauty pageant, which aims to open doors for the wheelchair-bound in modelling, film and television, according to organisers  Slideshow 

(Reuters) - GlaxoSmithKline Plc said U.S. health regulators had approved its drug Promacta for the additional use of treating low platelet count in hepatitis C patients that will allow them to undergo a standard therapy for the liver disease.

The drug, already approved as a treatment for idiopathic thrombocytopenic purpura — low platelet count of unknown cause — was developed along with Ligand Pharmaceuticals Inc.

Ligand shares rose as much as 17 percent in heavy volumes by mid-day on the Nasdaq.

"We believe that Promacta sales are set to see an uptick with approval in a significant population with unmet medical need," Roth Capital analyst Joseph Pantginis said in a note.

About 3.2 million people in the United States have chronic hepatitis C, the most common blood-borne virus, according to the U.S. Centers for Disease Control and Prevention.

Pantginis estimated Promacta sales of $328 million in 2013, corresponding to $24.6 million in revenue for Ligand.

"We maintain our belief that Glaxo is committed to growing the Promacta franchise with approval in additional indications with about 20 clinical trials ongoing," the analyst added.

The drug, also known as eltrombopag, is approved in 90 countries and is marketed under the brand name Promacta in the United States and as Revolade elsewhere.

It is now the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based hepatitis C therapy due to low platelet counts.

The U.S. Food and Drug Administration's approval was based on results from two late-stage studies that collectively enrolled 1,521 patients.

(Reporting by Prateek Kumar in Bangalore; Editing by Saumyadeb Chakrabarty)

FILED UNDER:

Ebola Outbreak

Reuters Showcase

Ebola Crisis

Ebola Crisis

U.N. to miss Dec 1 Ebola target due to rising Sierra Leone cases.  Full Article 

Tobacco Curbs

Tobacco Curbs

China considers tougher tobacco controls: Xinhua.  Full Article 

Reuters Exclusive

Reuters Exclusive

Pay per puff? Caffeine stick? E-cigarette boom sparks race for new patents  Full Article 

Healthy Diet

Healthy Diet

Studies examine U.S. meals in schools.  Full Article 

Fatal Accidents

Fatal Accidents

Helmets, engine size important in child deaths on ATVs.  Full Article 

Fertility Woes

Fertility Woes

Little understood chemicals cut men’s fertility.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage